Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

Douglas L. Mann, John J V McMurray, Milton Packer, Karl Swedberg, Jeffrey S. Borer, Wilson S. Colucci, Jacques Djian, Helmut Drexler, Arthur Feldman, Lars Kober, Henry Krum, Peter Liu, Markku Nieminen, Luigi Tavazzi, Dirk Jan Van Veldhuisen, Anders Waldenstrom, Marshelle Warren, Arne Westheim, Faiez Zannad, Thomas Fleming

Research output: Contribution to journalArticle

779 Citations (Scopus)

Abstract

Background - Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure. Methods and Results - Patients with New York Heart Association class II to IV chronic heart failure and a left ventricular ejection fraction ≤0.30 were enrolled in 2 clinical trials that differed only in the doses of etanercept used. In RECOVER, patients received placebo (n=373) or subcutaneous etanercept in doses of 25 mg every week (n=375) or 25 mg twice per week (n=375). In RENAISSANCE, patients received placebo (n=309), etanercept 25 mg twice per week (n=308), or etanercept 25 mg 3 times per week (n=308). The primary end point of each individual trial was clinical status at 24 weeks. Analysis of the effect of the 2 higher doses of etanercept on the combined outcome of death or hospitalization due to chronic heart failure from the 2 studies was also planned (RENEWAL). On the basis of prespecified stopping rules, both trials were terminated prematurely owing to lack of benefit. Etanercept had no effect on clinical status in RENAISSANCE (P=0.17) or RECOVER (P=0.34) and had no effect on the death or chronic heart failure hospitalization end point in RENEWAL (etanercept to placebo relative risk=1.1, 95% CI 0.91 to 1.33, P=0.33). Conclusions - The results of RENEWAL rule out a clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic heart failure.

Original languageEnglish (US)
Pages (from-to)1594-1602
Number of pages9
JournalCirculation
Volume109
Issue number13
DOIs
StatePublished - Apr 6 2004

Fingerprint

Heart Failure
Therapeutics
Hospitalization
Placebos
Etanercept
Clinical Trials
Stroke Volume
Theoretical Models
Tumor Necrosis Factor-alpha
Mortality

Keywords

  • Cytokines
  • Etanercept
  • Heart failure
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., ... Fleming, T. (2004). Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation, 109(13), 1594-1602. https://doi.org/10.1161/01.CIR.0000124490.27666.B2

Targeted Anticytokine Therapy in Patients with Chronic Heart Failure : Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). / Mann, Douglas L.; McMurray, John J V; Packer, Milton; Swedberg, Karl; Borer, Jeffrey S.; Colucci, Wilson S.; Djian, Jacques; Drexler, Helmut; Feldman, Arthur; Kober, Lars; Krum, Henry; Liu, Peter; Nieminen, Markku; Tavazzi, Luigi; Van Veldhuisen, Dirk Jan; Waldenstrom, Anders; Warren, Marshelle; Westheim, Arne; Zannad, Faiez; Fleming, Thomas.

In: Circulation, Vol. 109, No. 13, 06.04.2004, p. 1594-1602.

Research output: Contribution to journalArticle

Mann, DL, McMurray, JJV, Packer, M, Swedberg, K, Borer, JS, Colucci, WS, Djian, J, Drexler, H, Feldman, A, Kober, L, Krum, H, Liu, P, Nieminen, M, Tavazzi, L, Van Veldhuisen, DJ, Waldenstrom, A, Warren, M, Westheim, A, Zannad, F & Fleming, T 2004, 'Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)', Circulation, vol. 109, no. 13, pp. 1594-1602. https://doi.org/10.1161/01.CIR.0000124490.27666.B2
Mann, Douglas L. ; McMurray, John J V ; Packer, Milton ; Swedberg, Karl ; Borer, Jeffrey S. ; Colucci, Wilson S. ; Djian, Jacques ; Drexler, Helmut ; Feldman, Arthur ; Kober, Lars ; Krum, Henry ; Liu, Peter ; Nieminen, Markku ; Tavazzi, Luigi ; Van Veldhuisen, Dirk Jan ; Waldenstrom, Anders ; Warren, Marshelle ; Westheim, Arne ; Zannad, Faiez ; Fleming, Thomas. / Targeted Anticytokine Therapy in Patients with Chronic Heart Failure : Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). In: Circulation. 2004 ; Vol. 109, No. 13. pp. 1594-1602.
@article{467fdda2701542e0be90d78e21d9a4f3,
title = "Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)",
abstract = "Background - Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure. Methods and Results - Patients with New York Heart Association class II to IV chronic heart failure and a left ventricular ejection fraction ≤0.30 were enrolled in 2 clinical trials that differed only in the doses of etanercept used. In RECOVER, patients received placebo (n=373) or subcutaneous etanercept in doses of 25 mg every week (n=375) or 25 mg twice per week (n=375). In RENAISSANCE, patients received placebo (n=309), etanercept 25 mg twice per week (n=308), or etanercept 25 mg 3 times per week (n=308). The primary end point of each individual trial was clinical status at 24 weeks. Analysis of the effect of the 2 higher doses of etanercept on the combined outcome of death or hospitalization due to chronic heart failure from the 2 studies was also planned (RENEWAL). On the basis of prespecified stopping rules, both trials were terminated prematurely owing to lack of benefit. Etanercept had no effect on clinical status in RENAISSANCE (P=0.17) or RECOVER (P=0.34) and had no effect on the death or chronic heart failure hospitalization end point in RENEWAL (etanercept to placebo relative risk=1.1, 95{\%} CI 0.91 to 1.33, P=0.33). Conclusions - The results of RENEWAL rule out a clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic heart failure.",
keywords = "Cytokines, Etanercept, Heart failure, Tumor necrosis factor",
author = "Mann, {Douglas L.} and McMurray, {John J V} and Milton Packer and Karl Swedberg and Borer, {Jeffrey S.} and Colucci, {Wilson S.} and Jacques Djian and Helmut Drexler and Arthur Feldman and Lars Kober and Henry Krum and Peter Liu and Markku Nieminen and Luigi Tavazzi and {Van Veldhuisen}, {Dirk Jan} and Anders Waldenstrom and Marshelle Warren and Arne Westheim and Faiez Zannad and Thomas Fleming",
year = "2004",
month = "4",
day = "6",
doi = "10.1161/01.CIR.0000124490.27666.B2",
language = "English (US)",
volume = "109",
pages = "1594--1602",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Targeted Anticytokine Therapy in Patients with Chronic Heart Failure

T2 - Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

AU - Mann, Douglas L.

AU - McMurray, John J V

AU - Packer, Milton

AU - Swedberg, Karl

AU - Borer, Jeffrey S.

AU - Colucci, Wilson S.

AU - Djian, Jacques

AU - Drexler, Helmut

AU - Feldman, Arthur

AU - Kober, Lars

AU - Krum, Henry

AU - Liu, Peter

AU - Nieminen, Markku

AU - Tavazzi, Luigi

AU - Van Veldhuisen, Dirk Jan

AU - Waldenstrom, Anders

AU - Warren, Marshelle

AU - Westheim, Arne

AU - Zannad, Faiez

AU - Fleming, Thomas

PY - 2004/4/6

Y1 - 2004/4/6

N2 - Background - Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure. Methods and Results - Patients with New York Heart Association class II to IV chronic heart failure and a left ventricular ejection fraction ≤0.30 were enrolled in 2 clinical trials that differed only in the doses of etanercept used. In RECOVER, patients received placebo (n=373) or subcutaneous etanercept in doses of 25 mg every week (n=375) or 25 mg twice per week (n=375). In RENAISSANCE, patients received placebo (n=309), etanercept 25 mg twice per week (n=308), or etanercept 25 mg 3 times per week (n=308). The primary end point of each individual trial was clinical status at 24 weeks. Analysis of the effect of the 2 higher doses of etanercept on the combined outcome of death or hospitalization due to chronic heart failure from the 2 studies was also planned (RENEWAL). On the basis of prespecified stopping rules, both trials were terminated prematurely owing to lack of benefit. Etanercept had no effect on clinical status in RENAISSANCE (P=0.17) or RECOVER (P=0.34) and had no effect on the death or chronic heart failure hospitalization end point in RENEWAL (etanercept to placebo relative risk=1.1, 95% CI 0.91 to 1.33, P=0.33). Conclusions - The results of RENEWAL rule out a clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic heart failure.

AB - Background - Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure. Methods and Results - Patients with New York Heart Association class II to IV chronic heart failure and a left ventricular ejection fraction ≤0.30 were enrolled in 2 clinical trials that differed only in the doses of etanercept used. In RECOVER, patients received placebo (n=373) or subcutaneous etanercept in doses of 25 mg every week (n=375) or 25 mg twice per week (n=375). In RENAISSANCE, patients received placebo (n=309), etanercept 25 mg twice per week (n=308), or etanercept 25 mg 3 times per week (n=308). The primary end point of each individual trial was clinical status at 24 weeks. Analysis of the effect of the 2 higher doses of etanercept on the combined outcome of death or hospitalization due to chronic heart failure from the 2 studies was also planned (RENEWAL). On the basis of prespecified stopping rules, both trials were terminated prematurely owing to lack of benefit. Etanercept had no effect on clinical status in RENAISSANCE (P=0.17) or RECOVER (P=0.34) and had no effect on the death or chronic heart failure hospitalization end point in RENEWAL (etanercept to placebo relative risk=1.1, 95% CI 0.91 to 1.33, P=0.33). Conclusions - The results of RENEWAL rule out a clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic heart failure.

KW - Cytokines

KW - Etanercept

KW - Heart failure

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=11144355760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144355760&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000124490.27666.B2

DO - 10.1161/01.CIR.0000124490.27666.B2

M3 - Article

C2 - 15023878

AN - SCOPUS:11144355760

VL - 109

SP - 1594

EP - 1602

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 13

ER -